PROF:NASDAQProfound Medical Corp. analysis

Profound Medical Corp. posted a spectacular 104% revenue surge in the latest quarter, driving year‑over‑year revenue growth to 43% and lifting gross margins to an impressive 71%. The company’s cash balance of roughly $60 M comfortably exceeds its modest debt load, providing a solid runway despite operating losses and a negative EBITDA. Analyst sentiment is overwhelmingly positive, with a consensus “strong buy” rating, a median 12‑month target of $11.20 and an implied upside of over 60%. The market sentiment index is at “Extreme Greed,” underscoring strong investor enthusiasm.
Technically, the stock trades just below its 20‑day SMA (6.93) but remains above the 50‑day and 200‑day SMAs, supporting a bullish bias, while the RSI sits near the neutral 51 level. However, the MACD histogram is negative and the MACD line sits under its signal, hinting at short‑term momentum weakness. Volatility is high at ~57% over the past 30 days and beta exceeds 1.7, indicating pronounced price swings. With a current price of $6.90 versus a support around $6.50 and resistance near $7.89, the stock is positioned for a potential breakout if earnings momentum sustains.